- Home
- GILD vs AXP Comparison
GILD vs AXP Comparison
Compare GILD & AXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GILD | AXP |
|---|---|---|
| Founded | 1987 | 1850 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4B | 254.8B |
| IPO Year | 2000 | 2004 |
Fundamental Metrics
Financial Performance| Metric | GILD | AXP |
|---|---|---|
| Price | $146.19 | $302.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 21 |
| Target Price | $146.50 | ★ $336.80 |
| AVG Volume (30 Days) | ★ 5.7M | 3.8M |
| Earning Date | 05-13-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.25% | 1.07% |
| EPS Growth | ★ 1684.21 | 9.78 |
| EPS | 6.78 | ★ 15.38 |
| Revenue | $24,689,000,000.00 | ★ $27,819,000,000.00 |
| Revenue This Year | $4.68 | $19.24 |
| Revenue Next Year | $6.10 | $8.82 |
| P/E Ratio | $21.53 | ★ $19.89 |
| Revenue Growth | 9.98 | ★ 13.44 |
| 52 Week Low | $95.30 | $220.43 |
| 52 Week High | $157.29 | $387.49 |
Technical Indicators
Market Signals| Indicator | GILD | AXP |
|---|---|---|
| Relative Strength Index (RSI) | 50.61 | 33.50 |
| Support Level | $143.09 | $301.73 |
| Resistance Level | $157.29 | $308.71 |
| Average True Range (ATR) | 3.22 | 9.19 |
| MACD | -1.02 | -0.75 |
| Stochastic Oscillator | 34.57 | 15.81 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About AXP American Express Company
American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products. The company also operates a highly profitable merchant payment network. It operates in four segments: US consumer services, US commercial services, international card services, and global merchant and network services. In addition to payment products, the company's commercial business offers expense management tools, consulting services, and business loans.